

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**201281Orig1s000**

**CHEMISTRY REVIEW(S)**

**FDA CDER EES  
ESTABLISHMENT EVALUATION REQUEST  
DETAIL REPORT**

**Application:** NDA 201281/000  
**Start Date:** 19-JAN-2011  
**Regulatory:** 30-JAN-2012

**Action Goal:**  
**District Goal:** 01-DEC-2011

**Applicant:** BOEHRINGER PHARMS  
900 RIDGEBURY RD  
RIDGEFIELD, CT 06877

**Brand Name:** Linagliptin + Metformin Fixed Dose Combi  
**Estab. Name:** Linagliptin + Metformin Fixed Dose Combination Tablets  
**Generic Name:**

**Priority:** 4  
**Org. Code:** 510

**Product Number; Dosage Form; Ingredient; Strengths**  
001; TABLET; LINAGLIPTIN; 2.5MG  
001; TABLET; METFORMIN HYDROCHLORIDE; 500MG  
002; TABLET; LINAGLIPTIN; 2.5MG  
002; TABLET; METFORMIN HYDROCHLORIDE; 850MG  
003; TABLET; LINAGLIPTIN; 2.5MG  
003; TABLET; METFORMIN HYDROCHLORIDE; 1000MG

**Application Comment:** PLEASE SEE BELOW FOR ESTABLISHMENT COMMENTS (on 21-JAN-2011 by K. SHARMA ( ))

**FDA Contacts:** K. SHARMA Project Manager  
S. TRAN Team Leader 301-796-1764

---

<b>Overall Recommendation:</b>	ACCEPTABLE	on 20-DEC-2011	by D. SMITH	( )
	WITHHOLD	on 15-NOV-2011	by D. SMITH	( )
	WITHHOLD	on 22-AUG-2011	by EES_PROD	

---

**FDA CDER EES  
ESTABLISHMENT EVALUATION REQUEST  
DETAIL REPORT**

**Establishment:** CFN: (b) (4)  
(b) (4)

**FEI:** (b) (4)

**DMF No:** **AADA:**

**Responsibilities:** FINISHED DOSAGE RELEASE TESTER  
FINISHED DOSAGE STABILITY TESTER

**Establishment Comment:** ALTERNATE SITE OF TESTING (RELEASE NAD STABILITY) FOR DRUG PRODUCT (on 21-JAN-2011 by K. SHARMA ( ))

**Profile:** CONTROL TESTING LABORATORY **OAI Status:** NONE

<u>Milestone Name</u>	<u>Milestone Date</u>	<u>Request Type</u>	<u>Planned Completion</u>	<u>Decision</u>	<u>Creator</u>
<u>Comment</u>				<u>Reason</u>	
SUBMITTED TO OC	25-JAN-2011				SHARMAKH
OC RECOMMENDATION	26-JAN-2011			ACCEPTABLE BASED ON PROFILE	INYARDA
SUBMITTED TO OC	02-DEC-2011				PATWARDHAN
OC RECOMMENDATION	04-DEC-2011			ACCEPTABLE BASED ON PROFILE	STOCKM

**FDA CDER EES  
ESTABLISHMENT EVALUATION REQUEST  
DETAIL REPORT**

Establishment: CFN: [REDACTED] FEI: [REDACTED] (b) (4)

DMF No: AADA:

Responsibilities: FINISHED DOSAGE RELEASE TESTER  
FINISHED DOSAGE STABILITY TESTER

Establishment Comment: ALTERNATE SITE FOR TESTING (RELEASE AND STABILITY FOR THE DRUG PRODUCT) (on 18-FEB-2011 by K. SHARMA ( ))  
Profile: CONTROL TESTING LABORATORY OAI Status: NONE

<u>Milestone Name</u>	<u>Milestone Date</u>	<u>Request Type</u>	<u>Planned Completion</u>	<u>Decision</u>	<u>Creator</u>
<u>Comment</u>				<u>Reason</u>	
SUBMITTED TO OC	18-FEB-2011				SHARMAKH
SUBMITTED TO DO	22-FEB-2011	Product Specific			TOULOUSEM
ASSIGNED INSPECTION TO IB	24-FEB-2011	Product Specific			PHILPYE
INSPECTION PERFORMED	[REDACTED] (b) (4)				JOSE.CRUZ
<p>Inspection of this contract control-testing facility was conducted as requested by HFC-130 (DFFI), under FACTS assignment # 6757605, to cover the chemical testing activities related to Linagliptin / Metformin HCl Tablets 2.5 mg / 500 mg, 2.5 mg / 850 mg, 2.5 mg / 1000 mg in connection with review of NDA # 201-281.</p> <p>This is the first time this contract testing facility is inspected by FDA. Current inspection disclosed no objectionable conditions and no FDA-483 was issued. Two verbal observations were discussed with firm's management. The verbal observations were as follows: personnel training procedures have no requirement for the analysts' GMP training on a continued (yearly) basis, and sample intermediate-storage room not mapped-studied under conditions representative of routine sample storage conditions.</p> <p>→ firm's management committed to provide continued GMP training to analysts and to qualify the sample storage area under loaded conditions.</p>					
INSPECTION SCHEDULED	[REDACTED] (b) (4)				IRIVERA
DO RECOMMENDATION	19-SEP-2011			ACCEPTABLE INSPECTION	STOCKM
OC RECOMMENDATION	20-SEP-2011			ACCEPTABLE DISTRICT RECOMMENDATION	INYARDA
SUBMITTED TO OC	02-DEC-2011				PATWARDHAN
OC RECOMMENDATION	04-DEC-2011			ACCEPTABLE BASED ON PROFILE	STOCKM

**FDA CDER EES  
ESTABLISHMENT EVALUATION REQUEST  
DETAIL REPORT**

**Establishment:** CFN: 9610492 FEI: 3002806556  
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG  
BINGER STREET 173  
INGELHEIM AM RHEIN, , GERMANY

**DMF No:** **AADA:**

**Responsibilities:** DRUG SUBSTANCE LABELER  
DRUG SUBSTANCE MANUFACTURER  
DRUG SUBSTANCE PACKAGER  
DRUG SUBSTANCE STABILITY TESTER  
FINISHED DOSAGE LABELER  
FINISHED DOSAGE MANUFACTURER  
FINISHED DOSAGE PACKAGER  
FINISHED DOSAGE RELEASE TESTER  
FINISHED DOSAGE STABILITY TESTER

**Establishment Comment:** IN ADDITION, ALSO RESPONSIBLE FOR TESTING OF EXCIPIENTS AND METFORMIN (on 02-DEC-2011 by S. PATWARDHAN (HF-01) 301-796-4085)  
ALL ASPECTS OF MANUFACTURING, PACKAGING, LABELING AND TESTING (RELEASE AND STABILITY) FOR DRUG PRODUCT (on 21-JAN-2011 by K. SHARMA ( ))  
ALL ASPECTS OF THE MANUFACTURING (b) (4) PACKAGING, LABELING, QUALITY CONTROL OPERATIONS, AND STABILITY TESTING FOR DRUG SUBSTANCE LINAGLIPTIN (on 21-JAN-2011 by K. SHARMA ( ))  
**Profile:** NON-STERILE API BY CHEMICAL SYNTHESIS **OAI Status:** NONE

TABLETS, PROMPT RELEASE NONE

<u>Milestone Name</u>	<u>Milestone Date</u>	<u>Request Type</u>	<u>Planned Completion</u>	<u>Decision</u>	<u>Creator</u>
<u>Comment</u>				<u>Reason</u>	
SUBMITTED TO OC	25-JAN-2011				SHARMAKH
OC RECOMMENDATION	26-JAN-2011			ACCEPTABLE BASED ON PROFILE	INYARDA
SUBMITTED TO OC	02-DEC-2011				PATWARDHAN
OC RECOMMENDATION	04-DEC-2011			ACCEPTABLE BASED ON PROFILE	STOCKM
SUBMITTED TO OC	25-JAN-2011				SHARMAKH
SUBMITTED TO DO	26-JAN-2011	10-Day Letter			INYARDA
DO RECOMMENDATION	31-JAN-2011			ACCEPTABLE BASED ON FILE REVIEW	PHILPYE
OC RECOMMENDATION	02-FEB-2011			ACCEPTABLE DISTRICT RECOMMENDATION	SMITHDE
SUBMITTED TO OC	02-DEC-2011				PATWARDHAN
SUBMITTED TO DO	04-DEC-2011	10-Day Letter			STOCKM
DO RECOMMENDATION	20-DEC-2011			ACCEPTABLE BASED ON FILE REVIEW	PHILPYE

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.